A recent (10/08/2020)article in The New England Journal of Medicine details the results of a randomized clinical trial designed to evaluate the efficacy of remdesivir for treating adults with severe Covid-19.As per the authors:

"We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. "

The following Kaplan-Meier curves show the time to recovery distributions separately for the remdesivir and placebo samples.Patients were followed for up to 28 weeks after receiving the initial 200 mg dose of remdesivir (or placebo), until they either recovered from Coivid-19 or were censored (discharged prior to recovery, or still had not recovered at the end of the study follow-up).The shaded areas around each curve show the confidence interval endpoints for each point on the curve.At the end of 28 days, approximately 74% of 541 patients randomized to the remdesivir group had recovered, and 68% of the 521 patients randomized to the placebo arm had recovered.

The incidence rate ratio (and 95% confidence interval) of recovery for the remdesivir group compared to the placebo group is 1.29 (1.12, 1.49).

Approximately how many more Covid-19 patients (from the same population from which the study participants were taken) would be expected to recover from Covid-19 within 28 days, if 2,000 such patients were treated with remdesivir, versus if these 2,000 patients were not treated with remdesivir (or any other treatment)?

a. 1,480

b. 120

c. 580

d. 1,360

1point